Skip to main content
Medivir logo

Medivir — Investor Relations & Filings

Ticker · MVIR ISIN · SE0020181014 LEI · 549300VWDGUX0WMJ1T79 ST Manufacturing
Open in API
Filings indexed 965 across all filing types
Latest filing 2015-08-20 Interim / Quarterly Rep…
Country SE Sweden
Listing ST MVIR

About Medivir

https://www.medivir.com/

Medivir is a pharmaceutical company specializing in the discovery and clinical development of innovative drugs for cancer. The company focuses on oncology areas with high unmet medical needs, aiming to provide transformative treatments for patients with limited therapeutic options. Its research and development strategy is based on extensive expertise in drug design, particularly targeting enzymes such as proteases and polymerases, and includes the use of a proprietary prodrug platform. Medivir actively pursues collaborations with academic and industrial partners to advance its pipeline from research through to commercialization.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2015
Interim / Quarterly Report Classification · 100% confidence The document is titled 'MEDIVIR AB – INTERIM REPORT, SECOND QUARTER 2015'. It contains comprehensive financial statements, including income statements, cash flow data, and detailed management commentary on business performance, research projects, and financial results for the specified period. It is not a short announcement or a certification, but the full interim report itself. H1 2015
2015-08-20 English
Medivir announces that Janssen has started a phase I study to evaluate the effect of simeprevir and odalasvir on AL-335 pharmacokinetics
Regulatory Filings Classification · 95% confidence The document is a press release from Medivir announcing that Janssen has initiated a Phase I clinical trial for a combination drug therapy involving simeprevir and odalasvir. It details the study's objective, provides background on Hepatitis C, and includes standard company boilerplate and contact information. This type of announcement, detailing clinical trial progress or partnership updates, does not fit neatly into the specific financial reporting categories (like 10-K, ER, IR, or DIV). It is a general corporate update related to ongoing operations and research. Since it is a specific operational announcement that isn't covered by other codes (like M&A, Capital Change, or Director Dealing), the most appropriate classification is the general regulatory announcement fallback category, RNS (Regulatory Filings). The document length (3436 chars) is short, but it is the primary content, not an announcement *of* another report.
2015-08-03 English
Medivir tillkännager att Janssen har startat en fas I-studie för att utvärdera effekten av simeprevir och odalasvir på AL-335:s farmakokinetik
Regulatory Filings Classification · 95% confidence The document is a press release from Medivir AB announcing that Janssen has initiated a Phase I clinical trial for a drug combination related to Hepatitis C. It details the study's purpose, background on HCV, and provides standard company/contact information. Crucially, it ends with the statement: "Informationen är sådan som Medivir ska offentliggöra enligt lagen om värdepappersmarknaden. Informationen lämnades för offentliggörande den 3 augusti 2015, klockan 08.30 CET." This structure strongly indicates a formal regulatory announcement made to the market regarding a significant corporate/clinical development. Since it is not a full financial report (10-K, IR), an earnings release (ER), or a specific management/board change (MANG), it falls best under the general category for regulatory announcements that convey material, non-financial news, which is 'Regulatory Filings' (RNS). It is not a proxy statement (PSI), director dealing (DIRS), or capital change (CAP). Given the content is a specific clinical trial update released under market disclosure rules, RNS is the most appropriate general regulatory category.
2015-08-03 Swedish
Medivir meddelar start av en klinisk fas I-studie med polymerashämmaren AL-704 för behandling av hepatit C
Regulatory Filings Classification · 95% confidence The document is a press release from Medivir AB announcing the start of a Phase I clinical trial for their drug candidate AL-704 for Hepatitis C treatment. It details the study design (randomized, double-blind, placebo-controlled), the collaboration with Janssen, and provides context on the disease. This type of announcement, detailing a specific operational or clinical development milestone, is typically classified as a general regulatory announcement or news release, as it does not fit the specific definitions for financial reports (10-K, IR, ER), management changes (MANG), or capital structure changes (CAP). Given the options, 'Regulatory Filings' (RNS) serves as the best general category for significant, non-financial, operational news releases that must be made public, especially since it concludes with a statement about public disclosure obligations ('Informationen är sådan som Medivir ska offentliggöra enligt lagen om värdepappersmarknaden').
2015-07-29 Swedish
Medivir announces start of a phase I clinical trial of the nucleotide polymerase inhibitor AL-704 for treatment of hepatitis C
Regulatory Filings Classification · 90% confidence The document is a press release from Medivir announcing the start of a Phase I clinical trial for a drug candidate (AL-704) in collaboration with Janssen. It details the nature of the trial (safety, tolerability, pharmacokinetics), the target disease (HCV), and includes standard boilerplate information about the company and regulatory disclosure requirements (mentioning the Securities Markets Act and publication time). This type of announcement, detailing specific operational or clinical development milestones, does not fit neatly into the defined categories like 10-K (Annual Report), ER (Earnings Release), or CT (Call Transcript). It is a specific corporate update regarding R&D progress. Since it is a specific regulatory/corporate announcement that doesn't match the other specialized codes (like DIV, CAP, MANG, etc.), the most appropriate fallback category is Regulatory Filings (RNS), which serves as a general category for miscellaneous official announcements not covered elsewhere.
2015-07-29 English
Medivir announces that Janssen submitted supplemental New Drug Application to U.S. FDA for OLYSIO® (simeprevir) in combination with sofosbuvir
Regulatory Filings Classification · 90% confidence The document is a press release from Medivir announcing that Janssen submitted a supplemental New Drug Application (sNDA) to the U.S. FDA regarding the drug OLYSIO®. This announcement concerns regulatory action and clinical trial updates related to a pharmaceutical product. It is not a comprehensive annual report (10-K), an interim report (IR), an earnings release (ER), or a management discussion (MDA). Since it details a specific regulatory submission and clinical data update, it falls under the category of general corporate news or regulatory updates that don't fit the highly specific financial report codes. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for significant, non-financial regulatory news, although 'LTR' (Legal Proceedings Report) is sometimes used for FDA actions, RNS is broader for general regulatory announcements not related to litigation or specific financial filings. However, upon reviewing the definitions, this is a specific announcement about a regulatory submission, which is a type of corporate action announcement. Since there is no specific code for 'Regulatory Submission Announcement', and it is not a legal proceeding (LTR), the best fit among the provided codes for a significant, non-financial, non-management announcement is the general regulatory/miscellaneous category, RNS.
2015-07-24 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.